How should I manage a patient with chronic regurgitation and cough who has a normal EGD, negative Bravo pH monitoring, and normal esophageal manometry?

Management of Chronic Regurgitation and Cough with Negative Workup

In a patient with chronic regurgitation and cough who has normal EGD, negative Bravo pH monitoring, and normal manometry, you should pursue multidisciplinary evaluation for non-GI causes (ENT, pulmonary, allergy) rather than continuing empiric PPI therapy, as the negative objective testing rules out GERD as the primary etiology 1.

Algorithmic Approach

Step 1: Interpret Your Negative Testing

Your patient has completed comprehensive reflux testing that is negative:

• Normal EGD = No erosive esophagitis, no Barrett's esophagus
• Negative Bravo pH monitoring = No pathologic acid exposure
• Normal manometry = No achalasia, normal peristalsis

This combination effectively rules out GERD as the cause of symptoms 1, 2.

Step 2: Stop or Minimize PPI Therapy

• If the patient is currently on PPIs, these should be discontinued or tapered to the lowest dose, as there is no objective evidence supporting their use 1, 2
• Continuing PPIs in this scenario risks treating a placebo effect rather than actual disease 2

Step 3: Pursue Alternative Diagnoses

Primary recommendation: Refer to appropriate specialists based on symptom pattern 1:

For chronic cough:

• ENT evaluation for laryngeal pathology, post-nasal drip, laryngeal hypersensitivity
• Pulmonary evaluation for asthma, eosinophilic bronchitis, chronic bronchitis
• Allergy evaluation for allergic rhinitis, environmental triggers

For regurgitation without reflux:

• Consider rumination syndrome (behavioral disorder with postprandial regurgitation)
• Consider supragastric belching if belching is prominent
• Evaluate for gastroparesis if nausea/early satiety present

Step 4: Consider Functional Disorders

If non-GI workup is negative, consider disorders of gut-brain interaction 2:

• Functional heartburn/regurgitation - symptoms without objective reflux
• Esophageal hypervigilance - heightened awareness of normal physiologic events
• Cough hypersensitivity syndrome - amplified cough response to minimal stimuli 3

Management for functional disorders 2:

• Neuromodulators (tricyclic antidepressants, SSRIs, gabapentin)
• Behavioral interventions: cognitive behavioral therapy, hypnotherapy, diaphragmatic breathing
• Speech pathology referral for cough suppression techniques

Critical Pitfalls to Avoid

Pitfall #1: Continuing Indefinite PPI Therapy

The 2023 AGA guideline explicitly states that patients with negative reflux workup should NOT continue long-term PPI therapy 1. This represents inappropriate medication use and potential harm from unnecessary acid suppression.

Pitfall #2: Assuming "Negative Testing Means Nothing"

While up to 75% of patients with reflux-related cough lack typical GERD symptoms 3, your patient has had objective testing that is negative. This is fundamentally different from untested patients and should redirect your diagnostic approach away from GERD.

Pitfall #3: Ordering More Reflux Testing

Some clinicians consider pH-impedance monitoring on PPI therapy in this scenario. However, the 2022 AGA guideline reserves on-therapy testing for patients with proven GERD who have persistent symptoms despite treatment 2. Your patient does not have proven GERD, so this would not be appropriate.

Nuances in the Evidence

The 2023 AGA extraesophageal reflux guideline 1 provides the clearest algorithm: patients with extraesophageal symptoms (cough, regurgitation) and negative ambulatory reflux monitoring should be evaluated for non-GI disorders. This represents the highest quality, most recent guidance specific to your clinical scenario.

While older research 4, 5, 6 suggested empiric PPI trials for suspected reflux-related cough, the current guidelines have evolved to emphasize objective testing before long-term therapy 1, 2, particularly in patients without typical reflux symptoms.

The key distinction: Your patient has already completed the diagnostic evaluation and it was negative. This places them in a different management pathway than patients who have not yet been tested.

Specific Next Steps

1. Discontinue or minimize PPI if currently prescribed
2. Refer to ENT for laryngoscopy and evaluation of laryngeal pathology
3. Refer to pulmonology for spirometry, methacholine challenge, or induced sputum analysis
4. Consider allergy testing if environmental triggers suspected
5. If all negative, refer to gastroenterology behavioral specialist or speech pathology for cough hypersensitivity management 3